New options and old dilemmas in the treatment of patients with advanced colorectal cancer

Annals of Oncology

Volumn 15, Issue 10, 2004, Pages 1453-1459

  Punt, C J A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bevacizumab; Capecitabine; Cetuximab; Colorectal cancer; Irinotecan; Oxaliplatin

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CELECOXIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; UFT; VASCULOTROPIN;

ADVANCED CANCER; ALOPECIA; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG APPROVAL; DRUG COST; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; FEVER; HAND FOOT SYNDROME; HEALTH CARE COST; HUMAN; HYPERBILIRUBINEMIA; INFECTION; LIVER METASTASIS; LIVER RESECTION; NAUSEA; NAUSEA AND VOMITING; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW; SEPSIS; STOMATITIS;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; HUMANS; LIVER NEOPLASMS; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; SIGNAL TRANSDUCTION;

EID: 6944234851     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh383     Document Type: Review

References (50)

1. Köhne C-H, Wils J, Lorenz M et al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol 2003; 21: 3721-3728.
2. Levi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxatiplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 1997; 350: 681-686.
3. Advanced Colorectal Cancer Meta-Analysis Project. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994; 12: 960-969.
4. Punt CJA, Blanke CD, Zhang J, Hammershaimb L. Integrated analysis of overall survival in two randomised studies comparing 5-fluorouracil/leucovorin with or without trimetrexate in advanced colorectal cancer. Ann Oncol 2002; 13: 92-94.
5. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
6. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 1992; 10: 904-911.
7. Ackland SP, Moore M, Jones M et al. A meta-analysis of two randomized trials of early chemotherapy in asymptomatic metastatic colorectal cancer. Proc Am Soc Clin Oncol 2001; 20: 132a (Abstr 526).
8. Maughan TS, James RD, Kerr DJ et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicenter randomised trial. Lancet 2003; 361: 457-464.
9. André T, Figer A, Cervantes A et al. FOLFOX7 compared to FOLFOX4. Preliminary results of the randomized optimox study. Proc Am Soc Clin Oncol 2003; 22: 253 (Abstr 1016).
10. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19: 2282-2292.
11. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19: 4097-4106.
12. Douillard JY, Hoff PM, Skillings JR et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20: 3605-3616.
13. Carmichael J, Popiela T, Radstone D et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 203: 3617-3627.
14. Van Cutsem E, Hoff PM, Harper P et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomized, phase III trials. Br J Cancer 2004; 90: 1190-1197.
15. Cassidy J, Twelves C, Van Cutsem E et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5- fluorouracil/leucovorin. Ann Oncol 2002; 13: 566-575.
16. Borner MM, Schöffski P, de Wit R et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and lencovorin: a randomized crossover trial in advanced colorectal cancer. Eur J Cancer 2002; 38: 349-358.
17. Schnetzler B, Popova N, Sappino AP. Coronary spasm induced by capecitabine. Ann Oncol 2001; 12: 723-724.
18. Camps C, Godes M, Soler JJ. Possible cardiotoxicity induced by orally administered fluoropyrimidines. An Med Interna 1990; 7: 525-527.
19. Van Cutsem E, Findlay M, Osterwalder B et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 2000; 18: 1337-1345.
20. Pazdur R, Passere Y, Rhodes V et al. Phase II study of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal cancer. J Clin Oncol 1994; 12: 2296-2300.
21. Punt CJA, Nortier JW, ten Bokkel Huinink WW et al. Combination of irinotecan and capecitabine as first-line treatment in advanced colorectal cancer (ACC): results of a phase II trial. Eur J Cancer 2003; 1 (Suppl 5): S85 (Abstr 277).
22. Zeuli M, Nardoni C, Pino MS et al. Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. Ann Oncol 2003; 14: 1378-1382.
23. Borner MM, Dietrich D, Stupp R et al. Phase-II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 2002; 20: 1759-1766.
24. Grothey A, Jordan K, Kellner O et al. Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): updated results of a randomized phase II trial. Eur J Cancer 2003; S90 (Suppl 5): S90 (Abstr 295).
25. Petrioli R, Sabatino M, Fiaschi AI et al. UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer. Br J Cancer 2004; 90: 306-309.
26. Dunst J, Reese T, Sutter T et al. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 2002; 20: 3983-3991.
27. Rodel G, Grabenbauer GG, Papadopoulos T et al. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003; 21: 3098-3104.
28. Cunningham D, Pyrhönen S, James RD et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-1418.
29. Rothenberg ML, Oza AM, Bigelow RH et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21: 2059-2069.
30. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047.
31. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
32. Punt CJA. 'Hold the Mayo': solid facts or pulp fiction? Ann Oncol 2000; 11: 919-920.
33. Di Leo A, Buyse M, Bleiberg H. Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-11. Ann Oncol 2004; 15: 545-549.
34. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
35. Tournigand C, André T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reversed sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
36. Comella P, Casaretti R, De Rosa V et al. Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies. Ann Oncol 2002; 13: 1874-1881.
37. Ychou M, Conroy T, Seitz JF et al. An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin-5-fluorouracil every 2 weeks in patients with advanced solid tumors. Ann Oncol 2003; 14: 481-489.
38. Goetz MP, Erlichman C, Windebank AJ et al. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, fluorouracil, and leucovorin in patients with solid tumors. J Clin Oncol 2003; 21: 3761-3769.
39. Rothenberg ML, Berlin JD. Therapeutic strategies for metastatic colorectal cancer: simultaneous, sequential, or specific? J Clin Oncol 2003; 21: 3716-3717.
40. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209-1214.
41. Lenz HJ. Pharmacogenomics in colorectal cancer. Semin Oncol 2003; 30 (4 Suppl 15): 47-53.
42. Ruers T, Bleichrodt RP. Treatment of liver metastases, an update on the possibilities and results. Eur J Cancer 2002; 38: 1023-1033.
43. Goldberg RM, Fleming TR, Tangen CM et al. Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Ann Intern Med 1998; 129: 27-35.
44. Adam R. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann Oncol 2003; 14 (Supp] 2): ii13-ii16.
45. Saltz LB, Meropol NJ, Loehrer PJ Sr et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208.
46. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
47. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
48. Colorectal Cancer Collaborative Group. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. BMJ 2000; 321: 531-535.
49. Editorial. Who's afraid of the European Clinical Trials Directive? Lancet 2003; 361: 2167.
50. Meunier F, Lacombe D. European Organisation for Research and Treatment of Cancer's point of view. Lancet 2003; 362: 663.